Eugenio Mercuri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7109801/publications.pdf

Version: 2024-02-01

602 papers	33,331 citations	3525 90 h-index	7511 151 g-index
621 all docs	621 docs citations	621 times ranked	18996 citing authors

#	Article	IF	Citations
1	Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2017, 377, 1723-1732.	13.9	1,533
2	Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2018, 378, 625-635.	13.9	977
3	Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders, 2018, 28, 103-115.	0.3	584
4	Mutations in the Fukutin-Related Protein Gene (FKRP) Cause a Form of Congenital Muscular Dystrophy with Secondary Laminin Î±2 Deficiency and Abnormal Glycosylation of Î±-Dystroglycan. American Journal of Human Genetics, 2001, 69, 1198-1209.	2.6	563
5	Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet, The, 2003, 361, 736-742.	6.3	544
6	Duchenne muscular dystrophy. Nature Reviews Disease Primers, 2021, 7, 13.	18.1	448
7	Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Annals of Neurology, 2000, 48, 170-180.	2.8	440
8	Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp>uchenne muscular dystrophy. Annals of Neurology, 2016, 79, 257-271.	2.8	428
9	Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders, 2018, 28, 197-207.	0.3	421
10	Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain, 2007, 130, 2725-2735.	3.7	385
11	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	6.3	365
12	Spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2011, 6, 71.	1.2	363
13	Abnormal Magnetic Resonance Signal in the Internal Capsule Predicts Poor Neurodevelopmental Outcome in Infants With Hypoxic-Ischemic Encephalopathy. Pediatrics, 1998, 102, 323-328.	1.0	360
14	Muscle MRI in inherited neuromuscular disorders: Past, present, and future. Journal of Magnetic Resonance Imaging, 2007, 25, 433-440.	1.9	357
15	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	1.0	357
16	Muscular dystrophies. Lancet, The, 2013, 381, 845-860.	6.3	352
17	Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurology, The, 2012, 11, 443-452.	4.9	297
18	Early Prognostic Indicators of Outcome in Infants With Neonatal Cerebral Infarction: A Clinical, Electroencephalogram, and Magnetic Resonance Imaging Study. Pediatrics, 1999, 103, 39-46.	1.0	289

#	Article	IF	Citations
19	Muscular dystrophies. Lancet, The, 2019, 394, 2025-2038.	6.3	276
20	Optimality score for the neurologic examination of the infant at 12 and 18 months of age. Journal of Pediatrics, 1999, 135, 153-161.	0.9	262
21	The Childrenâ€™s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability. Neuromuscular Disorders, 2010, 20, 155-161.	0.3	239
22	Risdiplam in Type 1 Spinal Muscular Atrophy. New England Journal of Medicine, 2021, 384, 915-923.	13.9	229
23	Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Annals of Neurology, 2003, 53, 537-542.	2.8	219
24	Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Developmental Medicine and Child Neurology, 2016, 58, 77-84.	1.1	213
25	Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB Journal, 2007, 21, 1210-1226.	0.2	209
26	Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology, 2020, 94, e2270-e2282.	1.5	207
27	The Hammersmith Functional Motor Scale for Children with Spinal Muscular Atrophy: a Scale to Test Ability and Monitor Progress in Children with Limited Ambulation. European Journal of Paediatric Neurology, 2003, 7, 155-159.	0.7	187
28	Clinical and imaging findings in six cases of congenital muscular dystrophy with rigid spine syndrome linked to chromosome 1p (RSMD1). Neuromuscular Disorders, 2002, 12, 631-638.	0.3	176
29	Development of the <scp>P</scp>erformance of the <scp>U</scp>pper <scp>L</scp>imb module for <scp>D</scp>uchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2013, 55, 1038-1045.	1.1	173
30	Neonatal Cerebral Infarction and Neuromotor Outcome at School Age. Pediatrics, 2004, 113, 95-100.	1.0	172
31	Brain involvement in muscular dystrophies with defective dystroglycan glycosylation. Annals of Neurology, 2008, 64, 573-582.	2.8	172
32	Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscular Disorders, 2009, 19, 458-461.	0.3	171
33	North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2010, 20, 712-716.	0.3	171
34	Probabilistic diffusion tractography of the optic radiations and visual function in preterm infants at term equivalent age. Brain, 2008, 131, 573-582.	3.7	167
35	Congenital muscular dystrophies with defective glycosylation of dystroglycan. Neurology, 2009, 72, 1802-1809.	1.5	166
36	Revised upper limb module for spinal muscular atrophy: Development of a new module. Muscle and Nerve, 2017, 55, 869-874.	1.0	166

#	Article	IF	Citations
37	An optimality score for the neurologic examination of the term newborn. Journal of Pediatrics, 1998, 133, 406-416.	0.9	162
38	Prothrombotic Disorders and Abnormal Neurodevelopmental Outcome in Infants With Neonatal Cerebral Infarction. Pediatrics, 2001, 107, 1400-1404.	1.0	162
39	Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology, 2007, 68, 51-55.	1.5	159
40	Magnetic Resonance Image Correlates of Hemiparesis After Neonatal and Childhood Middle Cerebral Artery Stroke. Pediatrics, 2005, 115, 321-326.	1.0	158
41	Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores. Neurology, 2002, 59, 284-287.	1.5	157
42	Neurological and Perceptual-Motor Outcome at 5 - 6 Years of Age in Children with Neonatal Encephalopathy: Relationship with Neonatal Brain MRI. Neuropediatrics, 2002, 33, 242-248.	0.3	156
43	Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromuscular Disorders, 2005, 15, 303-310.	0.3	154
44	Functional changes in Duchenne muscular dystrophy. Neurology, 2011, 77, 250-256.	1.5	151
45	Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. European Journal of Human Genetics, 2005, 13, 256-259.	1.4	148
46	Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype. Nature Genetics, 2012, 44, 636-638.	9.4	148
47	Use of the Hammersmith Infant Neurological Examination in infants with cerebral palsy: a critical review of the literature. Developmental Medicine and Child Neurology, 2016, 58, 240-245.	1.1	145
48	Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 643-649.	0.3	144
49	Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues. Nucleic Acid Therapeutics, 2017, 27, 251-259.	2.0	144
50	Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine. Annals of Neurology, 2010, 67, 201-208.	2.8	143
51	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscular Disorders, 2016, 26, 126-131.	0.3	142
52	Natural history of Ullrich congenital muscular dystrophy. Neurology, 2009, 73, 25-31.	1.5	141
53	Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscular Disorders, 2005, 15, 164-171.	0.3	140
54	Neurofilament as a potential biomarker for spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2019, 6, 932-944.	1.7	137

#	Article	IF	Citations
55	Magnetic resonance imaging of muscle in congenital myopathies associated with RYR1 mutations. Neuromuscular Disorders, 2004, 14, 785-790.	0.3	135
56	Antepartum and Intrapartum Factors Preceding Neonatal Hypoxic-Ischemic Encephalopathy. Pediatrics, 2013, 132, e952-e959.	1.0	130
57	Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscular Disorders, 2004, 14, 130-135.	0.3	128
58	Head Growth in Infants With Hypoxicâ€“Ischemic Encephalopathy: Correlation With Neonatal Magnetic Resonance Imaging. Pediatrics, 2000, 106, 235-243.	1.0	127
59	General Movements Detect Early Signs of Hemiplegia in Term Infants with Neonatal Cerebral Infarction. Neuropediatrics, 2003, 34, 61-66.	0.3	126
60	Fracture prevalence in Duchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2002, 44, 695-698.	1.1	123
61	DPM2â€CDG: A muscular dystrophyâ€“dystroglycanopathy syndrome with severe epilepsy. Annals of Neurology, 2012, 72, 550-558.	2.8	121
62	Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation. Journal of Pediatrics, 2012, 161, 705-709.e1.	0.9	121
63	Does cranial ultrasound imaging identify arterial cerebral infarction in term neonates?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2005, 90, F252-f256.	1.4	118
64	Skeletal muscle pathology in autosomal dominant Emery-Dreifuss muscular dystrophy with lamin A/C mutations. Neuropathology and Applied Neurobiology, 2001, 27, 281-290.	1.8	117
65	Combined Use of Electroencephalogram and Magnetic Resonance Imaging in Full-Term Neonates With Acute Encephalopathy. Pediatrics, 2001, 107, 461-468.	1.0	115
66	Extreme Variability of Phenotype in Patients With an Identical Missense Mutation in the Lamin A/C Gene. Archives of Neurology, 2004, 61, 690.	4.9	114
67	Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. Brain, 2006, 129, 1260-1268.	3.7	114
68	Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurology, The, 2021, 20, 832-841.	4.9	112
69	Minor neurological signs and perceptual-motor difficulties in prematurely born children. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1997, 76, F9-F14.	1.4	111
70	Pilot trial of albuterol in spinal muscular atrophy. Neurology, 2002, 59, 609-610.	1.5	111
71	Novel mutations expand the clinical spectrum of DYNC1H1 -associated spinal muscular atrophy. Neurology, 2015, 84, 668-679.	1.5	106
72	A short protocol for muscle MRI in children with muscular dystrophies. European Journal of Paediatric Neurology, 2002, 6, 305-307.	0.7	105

#	Article	IF	Citations
73	Motor and perceptualâ€“motor competence in children with Down syndrome: variation in performance with age. European Journal of Paediatric Neurology, 1999, 3, 7-14.	0.7	104
74	Collagen VI involvement in Ullrich syndrome. Neurology, 2002, 58, 1354-1359.	1.5	103
75	Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurology, 2017, 17, 39.	0.8	102
76	A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscular Disorders, 2018, 28, 4-15.	0.3	102
77	Selective Muscle Involvement on Magnetic Resonance Imaging in Autosomal Dominant Emery-Dreifuss Muscular Dystrophy. Neuropediatrics, 2002, 33, 10-14.	0.3	101
78	The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309405.	0.9	99
79	24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2013, 8, e52512.	1.1	99
80	Magnetic resonance imaging of muscle in nemaline myopathy. Neuromuscular Disorders, 2004, 14, 779-784.	0.3	98
81	Cognitive Outcome at Early School Age in Term-Born Children With Perinatally Acquired Middle Cerebral Artery Territory Infarction. Stroke, 2008, 39, 403-410.	1.0	98
82	The everâ€expanding spectrum of congenital muscular dystrophies. Annals of Neurology, 2012, 72, 9-17.	2.8	98
83	Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. PLoS ONE, 2014, 9, e108205.	1.1	98
84	Ischaemic and haemorrhagic brain lesions in newborns with seizures and normal Apgar scores.. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1995, 73, F67-F74.	1.4	97
85	Correlation between visual function, neurodevelopmental outcome, and magnetic resonance imaging findings in infants with periventricular leucomalacia. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2000, 82, 134F-140.	1.4	97
86	Spectrum of Brain Changes in Patients With Congenital Muscular Dystrophy and FKRP Gene Mutations. Archives of Neurology, 2006, 63, 251.	4.9	97
87	Daily salbutamol in young patients with SMA type II. Neuromuscular Disorders, 2008, 18, 536-540.	0.3	97
88	Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings. Ophthalmology, 2018, 125, 218-226.	2.5	97
89	Developmental milestones in type I spinal muscular atrophy. Neuromuscular Disorders, 2016, 26, 754-759.	0.3	96
90	The Dubowitz neurological examination of the full-term newborn. Mental Retardation and Developmental Disabilities Research Reviews, 2005, 11, 52-60.	3.5	95

#	Article	IF	Citations
91	Application of the Sleep Disturbance Scale for Children (SDSC) in preschool age. European Journal of Paediatric Neurology, 2013, 17, 374-382.	0.7	95
92	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 513-522.	4.9	95
93	Neurologic examination in infants with hypoxic-ischemic encephalopathy at age 9 to 14 months: Use of optimality scores and correlation with magnetic resonance imaging findings. Journal of Pediatrics, 2001, 138, 332-337.	0.9	94
94	Muscle imaging in clinical practice: diagnostic value of muscle magnetic resonance imaging in inherited neuromuscular disorders. Current Opinion in Neurology, 2005, 18, 526-537.	1.8	94
95	Feeding problems and weight gain in Duchenne muscular dystrophy. European Journal of Paediatric Neurology, 2006, 10, 231-236.	0.7	94
96	TREAT-NMD workshop: Pattern recognition in genetic muscle diseases using muscle MRI. Neuromuscular Disorders, 2012, 22, S42-S53.	0.3	93
97	Mild phenotype of nemaline myopathy with sleep hypoventilation due to a mutation in the skeletal muscle Î±-actin (ACTA1) gene. Neuromuscular Disorders, 2001, 11, 35-40.	0.3	92
98	Feeding problems and malnutrition in spinal muscular atrophy type II. Neuromuscular Disorders, 2008, 18, 389-393.	0.3	92
99	Mutation Update and Genotype-Phenotype Correlations of Novel and Previously Described Mutations inTPM2andTPM3Causing Congenital Myopathies. Human Mutation, 2014, 35, 779-790.	1.1	92
100	The genetic basis of undiagnosed muscular dystrophies and myopathies. Neurology, 2016, 87, 71-76.	1.5	92
101	Fracture prevalence in Duchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2002, 44, 695-8.	1.1	89
102	Muscle Magnetic Resonance Imaging in Congenital Myopathies Due to Ryanodine Receptor Type 1 Gene Mutations. Archives of Neurology, 2011, 68, 1171.	4.9	89
103	Spinal muscular atrophy â€" insights and challenges in the treatment era. Nature Reviews Neurology, 2020, 16, 706-715.	4.9	89
104	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2022, 21, 42-52.	4.9	89
105	Neonatal Neurological Examination in Infants with Hypoxic Ischaemic Encephalopathy: Correlation with MRI Findings. Neuropediatrics, 1999, 30, 83-89.	0.3	86
106	Visual function in term infants with hypoxic-ischaemic insults: correlation with neurodevelopment at 2Âyears of age. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1999, 80, F99-F104.	1.4	85
107	Natural history of pulmonary function in collagen VI-related myopathies. Brain, 2013, 136, 3625-3633.	3.7	85
108	Neurologic examination of preterm infants at term age: Comparison with term infants. Journal of Pediatrics, 2003, 142, 647-655.	0.9	83

#	Article	IF	Citations
109	Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 201-206.	0.3	83
110	Nusinersen in type 1 spinal muscular atrophy: Twelveâ€month realâ€world data. Annals of Neurology, 2019, 86, 443-451.	2.8	83
111	Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade. American Journal of Medical Genetics, Part A, 2009, 149A, 140-146.	0.7	82
112	Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. Journal of Comparative Effectiveness Research, 2020, 9, 341-360.	0.6	82
113	Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.5	81
114	Risk Factors for Neonatal Arterial Ischemic Stroke: The Importance of the Intrapartum Period. Journal of Pediatrics, 2016, 173, 62-68.e1.	0.9	81
115	A short protocol for muscle MRI in children with muscular dystrophies. European Journal of Paediatric Neurology, 2002, 6, 305-307.	0.7	79
116	Cerebellar infarction and atrophy in infants and children with a history of premature birth. Pediatric Radiology, 1997, 27, 139-143.	1.1	77
117	Neurodevelopmental outcome at 12 and 18 months in late preterm infants. European Journal of Paediatric Neurology, 2010, 14, 503-507.	0.7	77
118	SEPN1 -related myopathies. Neurology, 2011, 76, 2073-2078.	1.5	77
119	Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurology, The, 2016, 15, 882-890.	4.9	77
120	Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. Journal of Neurology, 2014, 261, 152-163.	1.8	76
121	Thalamic atrophy in infants with PVL and cerebral visual impairment. Early Human Development, 2006, 82, 591-595.	0.8	75
122	Prevalence of congenital muscular dystrophy in Italy. Neurology, 2015, 84, 904-911.	1.5	75
123	A current approach to heart failure in Duchenne muscular dystrophy. Heart, 2017, 103, 1770-1779.	1.2	75
124	European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. European Journal of Paediatric Neurology, 2020, 28, 38-43.	0.7	74
125	Visual Function in Full-Term Infants with Hypoxic-Ischaemic Encephalopathy. Neuropediatrics, 1997, 28, 155-161.	0.3	72
126	Muscle magnetic resonance imaging in patients with congenital muscular dystrophy and Ullrich phenotype. Neuromuscular Disorders, 2003, 13, 554-558.	0.3	72

#	Article	IF	Citations
127	Sleep disorders in children with cerebral palsy: neurodevelopmental and behavioral correlates. Sleep Medicine, 2014, 15, 213-218.	0.8	72
128	Assessing upper limb function in nonambulant SMA patients: Development of a new module. Neuromuscular Disorders, 2011, 21, 406-412.	0.3	71
129	Association Study of Exon Variants in the NF-Î°B and TGFÎ² Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. American Journal of Human Genetics, 2016, 99, 1163-1171.	2.6	71
130	Upper Girdle Imaging in Facioscapulohumeral Muscular Dystrophy. PLoS ONE, 2014, 9, e100292.	1.1	71
131	Visual disorders in children with brain lesions:. European Journal of Paediatric Neurology, 2001, 5, 115-119.	0.7	70
132	MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients. Orphanet Journal of Rare Diseases, 2016, 11, 91.	1.2	70
133	Visual function of prematurely born children with and without perceptual-motor difficulties. Early Human Development, 1996, 45, 73-82.	0.8	69
134	Interpreting Genetic Variants in Titin in Patients With Muscle Disorders. JAMA Neurology, 2018, 75, 557.	4.5	69
135	An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials. CNS Drugs, 2019, 33, 919-932.	2.7	69
136	Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. Muscle and Nerve, 2005, 31, 602-609.	1.0	68
137	Swallowing difficulties in Duchenne muscular dystrophy: Indications for feeding assessment and outcome of videofluroscopic swallow studies. European Journal of Paediatric Neurology, 2008, 12, 239-245.	0.7	68
138	Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. European Journal of Paediatric Neurology, 2007, 11, 160-166.	0.7	67
139	Muscle MRI in Becker muscular dystrophy. Neuromuscular Disorders, 2012, 22, S100-S106.	0.3	67
140	A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2012, 54, 879-885.	1.1	67
141	Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool. PLoS ONE, 2017, 12, e0172346.	1.1	67
142	Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. Neuromuscular Disorders, 2018, 28, 582-585.	0.3	67
143	6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes. PLoS ONE, 2014, 9, e83400.	1.1	65
144	Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. PLoS ONE, 2018, 13, e0199657.	1.1	65

#	Article	IF	Citations
145	Somatosensory and Visual Evoked Potentials in Congenital Muscular Dystrophy: Correlation with MRI Changes and Muscle Merosin Status. Neuropediatrics, 1995, 26, 3-7.	0.3	64
146	Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscular Disorders, 2006, 16, 93-98.	0.3	64
147	Neurological examination of preterm infants at term equivalent age. Early Human Development, 2008, 84, 751-761.	0.8	64
148	Autosomal recessive Bethlem myopathy. Neurology, 2009, 73, 1883-1891.	1.5	64
149	Behavioral Profile in RASopathies. American Journal of Medical Genetics, Part A, 2014, 164, 934-942.	0.7	64
150	Evolution of Unilateral Perinatal Arterial Ischemic Stroke on Conventional and Diffusion-Weighted MR Imaging. American Journal of Neuroradiology, 2009, 30, 998-1004.	1.2	63
151	Neuropsychological development in children with Dravet syndrome. Epilepsy Research, 2011, 95, 86-93.	0.8	63
152	Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype. BMC Medical Genetics, 2012, 13, 73.	2.1	63
153	Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscular Disorders, 2013, 23, 451-455.	0.3	63
154	Muscular dystrophy. Current Opinion in Pediatrics, 2013, 25, 701-707.	1.0	63
155	Management of scoliosis in Duchenne muscular dystrophy: a large 10-year retrospective study. Developmental Medicine and Child Neurology, 2006, 48, 513.	1.1	63
156	Hand movements at 3â€ƒmonths predict later hemiplegia in term infants with neonatal cerebral infarction. Developmental Medicine and Child Neurology, 2010, 52, 767-772.	1.1	62
157	Nusinersen improves walking distance and reduces fatigue in laterâ€onset spinal muscular atrophy. Muscle and Nerve, 2019, 60, 409-414.	1.0	62
158	Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug Safety, 2021, 44, 1109-1119.	1.4	62
159	Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. Journal of Medical Genetics, 2010, 47, 856-858.	1.5	61
160	Revised upper limb module for spinal muscular atrophy: 12â€‰month changes. Muscle and Nerve, 2019, 59, 426-430.	1.0	61
161	Minicore myopathy in children: a clinical and histopathological study of 19 cases. Neuromuscular Disorders, 2000, 10, 264-273.	0.3	60
162	Duchenne muscular dystrophy and epilepsy. Neuromuscular Disorders, 2013, 23, 313-315.	0.3	60

#	Article	IF	Citations
163	Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle and Nerve, 2014, 49, 422-430.	1.0	60
164	Prognostic value of the neurologic optimality score at 9 and 18 months in preterm infants born before 31 weeks' gestation. Journal of Pediatrics, 2002, 140, 57-60.	0.9	59
165	Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia. Neuromuscular Disorders, 2004, 14, 689-693.	0.3	58
166	Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet Journal of Rare Diseases, 2021, 16, 430.	1.2	58
167	Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Therapeutics, 2022, 32, 29-39.	2.0	58
168	LMNA -associated myopathies. Neurology, 2014, 83, 1634-1644.	1.5	57
169	Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 576-583.	0.3	57
170	Therapeutic approaches for spinal muscular atrophy (SMA). Gene Therapy, 2017, 24, 514-519.	2.3	56
171	Pilot Trial of Salbutamol in Central Core and Multi-Minicore Diseases. Neuropediatrics, 2004, 35, 262-266.	0.3	55
172	Maturation of cerebral electrical activity and development of cortical folding in young very preterm infants. Clinical Neurophysiology, 2007, 118, 53-59.	0.7	55
173	Visual Function at 35 and 40 Weeks' Postmenstrual Age in Low-Risk Preterm Infants. Pediatrics, 2008, 122, e1193-e1198.	1.0	55
174	MRI in sarcoglycanopathies: a large international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 72-77.	0.9	55
175	Can the Griffiths scales predict neuromotor and perceptual-motor impairment in term infants with neonatal encephalopathy?. Archives of Disease in Childhood, 2004, 89, 637-643.	1.0	54
176	Neonatal cerebral infarction and visual function at school age. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2003, 88, 487F-491.	1.4	53
177	Cortical vision, MRI and developmental outcome in preterm infants. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2007, 93, F292-F297.	1.4	53
178	Relative frequency of congenital muscular dystrophy subtypes: Analysis of the UK diagnostic service 2001â€“2008. Neuromuscular Disorders, 2012, 22, 522-527.	0.3	53
179	Centronuclear myopathy related to dynamin 2 mutations: Clinical, morphological, muscle imaging and genetic features of an Italian cohort. Neuromuscular Disorders, 2013, 23, 229-238.	0.3	53
180	Visual function and perinatal focal cerebral infarction.. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1996, 75, F76-F81.	1.4	52

#	Article	IF	Citations
181	Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures. BMC Neurology, 2012, 12, 91.	0.8	52
182	Centronuclear myopathies: genotypeâ€“phenotype correlation and frequency of defined genetic forms in an Italian cohort. Journal of Neurology, 2015, 262, 1728-1740.	1.8	51
183	Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy TreatedÂwith Nusinersen. Journal of Pediatrics, 2020, 219, 223-228.e4.	0.9	51
184	Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. Journal of Neuromuscular Diseases, 2021, 8, 989-1001.	1.1	50
185	218th ENMC International Workshop:. Neuromuscular Disorders, 2017, 27, 596-605.	0.3	49
186	The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. Frontiers in Genetics, 2020, 11, 131.	1.1	49
187	Early and severe presentation of X-linked myotubular myopathy in a girl with skewed X-inactivation. Neuromuscular Disorders, 2003, 13, 55-59.	0.3	48
188	The Hammersmith functional score correlates with the SMN2 copy number: A multicentric study. Neuromuscular Disorders, 2007, 17, 400-403.	0.3	47
189	SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. European Journal of Human Genetics, 2010, 18, 52-58.	1.4	47
190	Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy. Neuromuscular Disorders, 2010, 20, 448-452.	0.3	47
191	IntragenicKANSL1mutations and chromosome 17q21.31 deletions: broadening the clinical spectrum and genotypeâ€“phenotype correlations in a large cohort of patients. Journal of Medical Genetics, 2015, 52, 804-814.	1.5	47
192	Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE, 2019, 14, e0218683.	1.1	47
193	Cardiomyopathy in Duchenne, Becker, and sarcoglycanopathies: A role for coronary dysfunction?. Muscle and Nerve, 1999, 22, 1549-1556.	1.0	46
194	Hypermyelinating neuropathy, mental retardation and epilepsy in a case of merosin deficiency. Neuromuscular Disorders, 2002, 12, 392-398.	0.3	46
195	MYO-MRI diagnostic protocols in genetic myopathies. Neuromuscular Disorders, 2019, 29, 827-841.	0.3	46
196	Visual Function Classification System for children with cerebral palsy: development and validation. Developmental Medicine and Child Neurology, 2020, 62, 104-110.	1.1	46
197	Visual function in children with hemiplegia in the first years of life. Developmental Medicine and Child Neurology, 2001, 43, 321.	1.1	46
198	Sequential study of central and peripheral nervous system involvement in an infant with merosin-deficient congenital muscular dystrophy. Neuromuscular Disorders, 1996, 6, 425-429.	0.3	45

#	Article	IF	Citations
199	Incidence of cranial ultrasound abnormalities in apparently well neonates on a postnatal ward: correlation with antenatal and perinatal factors and neurological status. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1998, 79, F185-F189.	1.4	45
200	MRI Lesions and Infants with Neonatal Encephalopathy. Is the Apgar Score Predictive?. Neuropediatrics, 2002, 33, 150-156.	0.3	45
201	Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. European Journal of Paediatric Neurology, 2002, 6, 153-159.	0.7	45
202	Early assessment of visual function in full term newborns. Early Human Development, 2008, 84, 107-113.	0.8	45
203	Sleep disturbances in preschool age children with cerebral palsy: a questionnaire study. Sleep Medicine, 2014, 15, 1089-1093.	0.8	45
204	Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS ONE, 2018, 13, e0199223.	1.1	45
205	Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet Journal of Rare Diseases, 2020, 15, 84.	1.2	45
206	Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. Neuromuscular Disorders, 2014, 24, 347-352.	0.3	44
207	Recessive mutations in MSTO1 cause mitochondrial dynamics impairment, leading to myopathy and ataxia. Human Mutation, 2017, 38, 970-977.	1.1	44
208	Can clinical signs identify newborns with neuromuscular disorders?. Journal of Pediatrics, 2005, 146, 73-79.	0.9	43
209	Clinical, neuroradiological and molecular characterization of cerebellar dysplasia with cysts (Porettiâ€“Boltshauser syndrome). European Journal of Human Genetics, 2016, 24, 1262-1267.	1.4	43
210	European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A). Journal of Neurology, 2020, 267, 45-56.	1.8	43
211	Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2016, 11, e0160195.	1.1	43
212	Strategy for mutation analysis in the autosomal recessive limb-girdle muscular dystrophies. Neuromuscular Disorders, 2001, 11, 80-87.	0.3	42
213	Visual disorders in children with brain lesions:. European Journal of Paediatric Neurology, 2001, 5, 107-114.	0.7	42
214	POMT2 mutation in a patient with â€˜MEB-likeâ€™ phenotype. Neuromuscular Disorders, 2006, 16, 446-448.	0.3	42
215	Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements. Neuromuscular Disorders, 2017, 27, 447-451.	0.3	42
216	Visual Outcome in Children with Congenital Hemiplegia: Correlation with MRI Findings. Neuropediatrics, 1996, 27, 184-188.	0.3	41

#	Article	IF	Citations
217	Perceptual-motor difficulties and their concomitants in six-year-old children born prematurely. Human Movement Science, 1998, 17, 629-653.	0.6	41
218	Whole-Body muscle MRI in a series of patients with congenital myopathy related to TPM2 gene mutations. Neuromuscular Disorders, 2012, 22, S137-S147.	0.3	41
219	Six minute walk test in type III spinal muscular atrophy: A 12month longitudinal study. Neuromuscular Disorders, 2013, 23, 624-628.	0.3	41
220	Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscular Disorders, 2015, 25, 749-753.	0.3	41
221	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	0.6	41
222	Muscular dystrophies due to defective glycosylation of dystroglycan. Acta Myologica, 2007, 26, 129-35.	1.5	41
223	Identification and characterization of novel collagen VI non-canonical splicing mutations causing ullrich congenital muscular dystrophy. Human Mutation, 2009, 30, E662-E672.	1.1	40
224	Early visual assessment in preterm infants with and without brain lesions: Correlation with visual and neurodevelopmental outcome at 12months. Early Human Development, 2011, 87, 177-182.	0.8	40
225	Early development in Dravet syndrome; visual function impairment precedes cognitive decline. Epilepsy Research, 2011, 93, 73-79.	0.8	40
226	Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. Neuromuscular Disorders, 2018, 28, 24-28.	0.3	40
227	Genetic therapies for inherited neuromuscular disorders. The Lancet Child and Adolescent Health, 2018, 2, 600-609.	2.7	40
228	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 492-502.	0.3	40
229	Motor coordination in children with congenital strabismus: Effects of late surgery. European Journal of Paediatric Neurology, 2007, 11, 285-291.	0.7	39
230	The use of muscle biopsy in the diagnosis of undefined ataxia with cerebellar atrophy in children. European Journal of Paediatric Neurology, 2012, 16, 248-256.	0.7	39
231	Prognostic value of the qualitative assessments of general movements in late-preterm infants. Early Human Development, 2013, 89, 1063-1066.	0.8	39
232	Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 96-105.	0.3	39
233	Sex differences in cerebral palsy on neuromotor outcome: a critical review. Developmental Medicine and Child Neurology, 2016, 58, 809-813.	1.1	39
234	Measuring Outcomes in Adults with Spinal Muscular Atrophy â€“ Challenges and Future Directions â€“ Meeting Report. Journal of Neuromuscular Diseases, 2020, 7, 523-534.	1.1	39

#	Article	IF	Citations
235	Congenital Hemiplegia in Children at School Age: Assessment of Hand Function in the Non-Hemiplegic Hand and Correlation with MRI. Neuropediatrics, 1999, 30, 8-13.	0.3	38
236	Bone Mineral Density in a Paediatric Spinal Muscular Atrophy Population. Neuropediatrics, 2004, 35, 325-328.	0.3	38
237	Congenital form of spinal muscular atrophy predominantly affecting the lower limbs: a clinical and muscle MRI study. Neuromuscular Disorders, 2004, 14, 125-129.	0.3	38
238	Visual function in infants with nonâ€syndromic craniosynostosis. Developmental Medicine and Child Neurology, 2007, 49, 574-576.	1.1	38
239	POMT1 and POMT2 mutations in CMD patients: A multicentric Italian study. Neuromuscular Disorders, 2008, 18, 565-571.	0.3	38
240	Movement Disorder-Childhood Rating Scale: Reliability and Validity. Pediatric Neurology, 2008, 39, 259-265.	1.0	38
241	Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience. Neuromuscular Disorders, 2017, 27, 1084-1086.	0.3	38
242	Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?. PLoS ONE, 2020, 15, e0230677.	1.1	38
243	Chiari I malformation in asymptomatic young children with williams syndrome: clinical and MRI study. European Journal of Paediatric Neurology, 1997, 1, 177-181.	0.7	37
244	Development of a patientâ€reported outcome measure for upper limb function in Duchenne muscular dystrophy: <scp>DMD</scp> Upper Limb <scp>PROM</scp>. Developmental Medicine and Child Neurology, 2017, 59, 224-231.	1.1	37
245	Cognitive profile in Duchenne muscular dystrophy boys without intellectual disability: The role of executive functions. Neuromuscular Disorders, 2018, 28, 122-128.	0.3	37
246	Congenital muscular dystrophy associated with calf hypertrophy, microcephaly and severe mental retardation in three Italian families: evidence for a novel CMD syndrome. Neuromuscular Disorders, 2000, 10, 541-547.	0.3	36
247	Visual performance and brain structures in the developing brain of pre-term infants. Early Human Development, 2010, 86, 73-75.	0.8	36
248	Novel de novo heterozygous loss-of-function variants in MED13L and further delineation of the MED13L haploinsufficiency syndrome. European Journal of Human Genetics, 2015, 23, 1499-1504.	1.4	36
249	6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction. Neuromuscular Disorders, 2017, 27, 879-882.	0.3	36
250	Evaluator Training and Reliability for SMA Global Nusinersen Trials1. Journal of Neuromuscular Diseases, 2018, 5, 159-166.	1.1	36
251	Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2020, 7, 786-798.	1.7	36
252	Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study. Neurology, 2021, 96, e587-e599.	1.5	36

#	Article	IF	Citations
253	Performance of Upper Limb module for Duchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2020, 62, 633-639.	1.1	35
254	Genotypeâ€“phenotype correlations in recessive titinopathies. Genetics in Medicine, 2020, 22, 2029-2040.	1.1	35
255	Type I SMA â€œnew natural historyâ€: longâ€term data in nusinersenâ€treated patients. Annals of Clinical and Translational Neurology, 2021, 8, 548-557.	1.7	35
256	Autosomal recessive congenital cerebellar atrophy. Brain and Development, 1993, 15, 439-445.	0.6	34
257	Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 14-18.	0.3	34
258	Long-term progression in type II spinal muscular atrophy. Neurology, 2019, 93, e1241-e1247.	1.5	34
259	Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp>. Annals of Neurology, 2020, 88, 1109-1117.	2.8	34
260	Muscle MRI findings in a three-generation family affected by Bethlem myopathy. European Journal of Paediatric Neurology, 2002, 6, 309-314.	0.7	34
261	Application of a scorable neurologic examination in healthy term infants aged 3 to 8 months. Journal of Pediatrics, 2003, 143, 546.	0.9	33
262	Visual function at school age in children with neonatal encephalopathy and low Apgar scores. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2004, 89, F258-F262.	1.4	33
263	Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 5-16.	0.3	33
264	Cognitive abilities in children with congenital muscular dystrophy: correlation with brain MRI and merosin status. Neuromuscular Disorders, 1999, 9, 383-387.	0.3	32
265	Congenital muscular dystrophies. Seminars in Pediatric Neurology, 2002, 9, 120-131.	1.0	32
266	Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS ONE, 2016, 11, e0151445.	1.1	32
267	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.3	32
268	MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients. Journal of Neurology, 2020, 267, 898-912.	1.8	32
269	Hammersmith Infant Neurological Examination for infants born preterm: predicting outcomes other than cerebral palsy. Developmental Medicine and Child Neurology, 2021, 63, 939-946.	1.1	32
270	Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency. Neuromuscular Disorders, 2012, 22, 685-689.	0.3	31

#	Article	IF	Citations
271	Next-generation sequencing approach to hyperCKemia. Neurology: Genetics, 2019, 5, e352.	0.9	31
272	Spinal muscular atrophy care in the COVIDâ€19 pandemic era. Muscle and Nerve, 2020, 62, 46-49.	1.0	31
273	Evaluation of the Corpus Callosum in Clumsy Children Born Prematurely: A Functional and Morphological Study. Neuropediatrics, 1996, 27, 317-322.	0.3	30
274	Neonatal neurological testing in resource-poor settings. Annals of Tropical Paediatrics, 2000, 20, 323-336.	1.0	30
275	Visual Function in Infants with West Syndrome: Correlation with EEG Patterns. Epilepsia, 2004, 45, 781-786.	2.6	30
276	Longitudinal cognitive assessment in healthy late preterm infants. European Journal of Paediatric Neurology, 2012, 16, 243-247.	0.7	30
277	Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. Journal of Medical Genetics, 2019, 56, 293-300.	1.5	30
278	The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 21-29.	0.3	30
279	A congenital myopathy with diaphragmatic weakness not linked to the SMARD1 locus. Neuromuscular Disorders, 2007, 17, 174-179.	0.3	29
280	Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry. Journal of Comparative Effectiveness Research, 2019, 8, 1187-1200.	0.6	29
281	Development of an academic disease registry for spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 794-799.	0.3	29
282	Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen. Neuromuscular Disorders, 2021, 31, 596-602.	0.3	29
283	Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. Journal of Comparative Effectiveness Research, 2022, 11, 139-155.	0.6	29
284	A new approach for neurological evaluation of infants in resource-poor settings. Annals of Tropical Paediatrics, 2002, 22, 355-368.	1.0	28
285	The neurological examination of the newborn baby. Early Human Development, 2005, 81, 947-956.	0.8	28
286	Serial casting of the ankles in Duchenne muscular dystrophy: can it be an alternative to surgery?. Neuromuscular Disorders, 2007, 17, 227-230.	0.3	28
287	CONGENITAL MUSCULAR DYSTROPHY WITH DEFECTIVE Î±-DYSTROGLYCAN, CEREBELLAR HYPOPLASIA, AND EPILEPSY. Neurology, 2009, 73, 1599-1601.	1.5	28
288	Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with theKCNJ11/S225T, del226-232 mutation. Pediatric Diabetes, 2012, 13, 656-660.	1.2	28

#	Article	IF	Citations
289	Early Neurodevelopmental Findings Predict School Age Cognitive Abilities in Duchenne Muscular Dystrophy: A Longitudinal Study. PLoS ONE, 2015, 10, e0133214.	1.1	28
290	Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2021, 8, 54-65.	1.7	28
291	Neurological 'soft' signs may identify children with sickle cell disease who are at risk for stroke. European Journal of Pediatrics, 1995, 154, 150-6.	1.3	28
292	Cerebral infarction in the newborn infant: Review of the literature and personal experience. European Journal of Paediatric Neurology, 1999, 3, 255-263.	0.7	27
293	Cortical Visual Function in Preterm Infants in the First Year. Journal of Pediatrics, 2010, 156, 550-555.	0.9	27
294	Enhanced human brain associative plasticity in Costello syndrome. Journal of Physiology, 2010, 588, 3445-3456.	1.3	27
295	Congenital muscular dystrophies with cognitive impairment. Neurology, 2010, 75, 898-903.	1.5	27
296	Cognitive decline in Dravet syndrome: Is there a cerebellar role?. Epilepsy Research, 2013, 106, 211-221.	0.8	27
297	Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. Neurology, 2020, 95, e1381-e1391.	1.5	27
298	Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2021, 8, 1622-1634.	1.7	27
299	Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. Archives of Disease in Childhood, 1999, 81, 442-443.	1.0	26
300	Neurological Examination at 6 to 9 Months in Infants with Cystic Periventricular Leukomalacia. Neuropediatrics, 2006, 37, 247-252.	0.3	26
301	Quality of Life in Parents of Children with Cerebral Palsy: Is it Influenced by the Child's Behaviour?. Neuropediatrics, 2010, 41, 121-126.	0.3	26
302	Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy. Muscle and Nerve, 2015, 52, 942-947.	1.0	26
303	Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study. Orphanet Journal of Rare Diseases, 2018, 13, 170.	1.2	26
304	A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 940-950.	0.3	26
305	Antenatal and Postnatal Brain Magnetic Resonance Imaging in Muscle-Eye-Brain Disease. Archives of Neurology, 2004, 61, 1301-6.	4.9	25
306	UK physiciansâ€™ attitudes and practices in long-term non-invasive ventilation of Duchenne Muscular Dystrophy. Developmental Neurorehabilitation, 2006, 9, 351-364.	1.1	25

#	Article	IF	Citations
307	Visual function in nonsyndromic craniosynostosis: past, present, and future. Child's Nervous System, 2007, 23, 1461-1465.	0.6	25
308	Long Term Memory Profile of Disorders Associated with Dysregulation of the RAS-MAPK Signaling Cascade. Behavior Genetics, 2011, 41, 423-429.	1.4	25
309	Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscular Disorders, 2020, 30, 756-764.	0.3	25
310	Orientation - Reversal and Phase - Reversal Visual Evoked Potentials in Full - Term Infants with Brain Lesions: A Longitudinal Study. Neuropediatrics, 1998, 29, 169-174.	0.3	24
311	Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy: Report of New Cases and Review of the Literature. Neuropediatrics, 2002, 33, 314-319.	0.3	24
312	Neonatal Brain MRI and Motor Outcome at School Age in Children with Neonatal Encephalopathy: A Review of Personal Experience. Neural Plasticity, 2003, 10, 51-57.	1.0	24
313	A homozygous COL6A2 intron mutation causes in-frame triple-helical deletion and nonsense-mediated mRNA decay in a patient with Ullrich congenital muscular dystrophy. Human Genetics, 2005, 117, 460-466.	1.8	24
314	Sequential Neurological Examinations in Infants with Neonatal Encephalopathy and Low Apgar Scores: Relationship with Brain MRI. Neuropediatrics, 2006, 37, 148-153.	0.3	24
315	An observational study of functional abilities in infants, children, and adults with type 1 SMA. Neurology, 2018, 91, e696-e703.	1.5	24
316	The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy. Acta Neuropathologica Communications, 2021, 9, 7.	2.4	24
317	Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Molecular Therapy - Methods and Clinical Development, 2021, 21, 76-82.	1.8	24
318	A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. Journal of Neuromuscular Diseases, 2022, 9, 39-52.	1.1	24
319	The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys. PLOS Currents, 2014, 6, .	1.4	24
320	Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase. Acta Myologica, 2020, 39, 57-66.	1.5	24
321	Periodic Lateralized Epileptiform Discharges (PLEDs) as Early Indicator of Stroke in Full-Term Newborns. Neuropediatrics, 2000, 31, 202-205.	0.3	23
322	Application of a Scorable Neurological Examination to Near-Term Infants: Longitudinal Data. Neuropediatrics, 2007, 38, 233-238.	0.3	23
323	The development of vision. Early Human Development, 2007, 83, 795-800.	0.8	23
324	Neurological examination of late-preterm infants at term age. European Journal of Paediatric Neurology, 2011, 15, 353-360.	0.7	23

#	Article	IF	Citations
325	Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes. Neuromuscular Disorders, 2015, 25, 212-215.	0.3	23
326	Duchenne Muscular Dystrophy Myogenic Cells from Urine-Derived Stem Cells Recapitulate the Dystrophin Genotype and Phenotype. Human Gene Therapy, 2016, 27, 772-783.	1.4	23
327	Longitudinal natural history in young boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2019, 29, 857-862.	0.3	23
328	Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placeboâ€controlled, doseâ€finding trial followed by 24â€‰months of treatment. European Journal of Neurology, 2023, 30, 1945-1956.	1.7	23
329	Assessment of Visual Function in Children with Methylmalonic Aciduria and Homocystinuria. Neuropediatrics, 2005, 36, 181-185.	0.3	22
330	Early assessment of visual function in preterm infants: How early is early?. Early Human Development, 2010, 86, 29-33.	0.8	22
331	Auditory processing in infancy: do early abnormalities predict disorders of language and cognitive development?. Developmental Medicine and Child Neurology, 2011, 53, 1085-1090.	1.1	22
332	FGF17, a gene involved in cerebellar development, is downregulated in a patient with Dandyâ€“Walker malformation carrying a de novo 8p deletion. Neurogenetics, 2011, 12, 241-245.	0.7	22
333	Gain and loss of abilities in type II SMA: A 12-month natural history study. Neuromuscular Disorders, 2020, 30, 765-771.	0.3	22
334	Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls. Journal of Neuromuscular Diseases, 2021, 8, 469-479.	1.1	22
335	Nusinersen efficacy data for 24â€month in type 2 and 3 spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2022, 9, 404-409.	1.7	22
336	Occipital sawtooth: a physiological EEG pattern in very premature infants. Clinical Neurophysiology, 2000, 111, 2145-2149.	0.7	21
337	Magnetic Resonance Imaging Assessment of Infantile Myofibromatosis. Clinical Radiology, 2002, 57, 67-70.	0.5	21
338	Application of a neonatal assessment of visual function in a population of low risk full-term newborn. Early Human Development, 2008, 84, 277-280.	0.8	21
339	Longitudinal assessment of visual development in non-syndromic craniosynostosis: a 1-year pre- and post-surgical study. Archives of Disease in Childhood, 2008, 93, 932-935.	1.0	21
340	Assessing Joint Hypermobility in Preschool-Aged Children. Journal of Pediatrics, 2016, 176, 162-166.	0.9	21
341	Cognitive-behavioral profiles in teenagers with Dravet syndrome. Brain and Development, 2016, 38, 554-562.	0.6	21
342	Congenital Muscular Dystrophy with Secondary Merosin Deficiency and Normal Brain MRI: A Novel Entity?. Neuropediatrics, 2000, 31, 186-189.	0.3	20

#	Article	IF	Citations
343	Cranial ultrasound abnormalities in full term infants in a postnatal ward: outcome at 12 and 18 months. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2000, 82, 128F-133.	1.4	20
344	Early and severe presentation of autosomal dominant Emery-Dreifuss muscular dystrophy (EMD2). Neurology, 2000, 54, 1704-1705.	1.5	20
345	Visual Function in Noonan and LEOPARD Syndrome. Neuropediatrics, 2008, 39, 335-340.	0.3	20
346	Implicit learning deficit in children with Duchenne muscular dystrophy: Evidence for a cerebellar cognitive impairment?. PLoS ONE, 2018, 13, e0191164.	1.1	20
347	Cognitive competence at the onset of West syndrome: correlation with EEG patterns and visual function. Developmental Medicine and Child Neurology, 2005, 47, 760.	1.1	20
348	Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. PLoS ONE, 2018, 13, e0199222.	1.1	20
349	Mechanisms and evolution of the brain damage in neonatal post-hemorrhagic hydrocephalus. Child's Nervous System, 1995, 11, 293-296.	0.6	19
350	The Effect of Behavioural States on Visual Evoked Responses in Preterm and Full-Term Newborns. Neuropediatrics, 1995, 26, 211-213.	0.3	19
351	Transcriptional behavior of DMD gene duplications in DMD/BMD males. Human Mutation, 2009, 30, E310-E319.	1.1	19
352	Muscle MRI in FHL1-linked reducing body myopathy. Neuromuscular Disorders, 2009, 19, 689-691.	0.3	19
353	Greater Sparing of Visual Search Abilities in Children After Congenital Rather Than Acquired Focal Brain Damage. Neurorehabilitation and Neural Repair, 2011, 25, 721-728.	1.4	19
354	Cardiac and muscle imaging findings in a family with X-linked Emeryâ€“Dreifuss muscular dystrophy. Neuromuscular Disorders, 2012, 22, 152-158.	0.3	19
355	Dandy-Walker malformation and Wisconsin syndrome: novel cases add further insight into the genotype-phenotype correlations of 3q23q25 deletions. Orphanet Journal of Rare Diseases, 2013, 8, 75.	1.2	19
356	A prospective longitudinal study on visuo-cognitive development in Dravet syndrome: Is there a â€œdorsal stream vulnerabilityâ€?. Epilepsy Research, 2015, 109, 57-64.	0.8	19
357	Syndromic Craniosynostosis Can Define New Candidate Genes for Suture Development or Result from the Non-specifc Effects of Pleiotropic Genes: Rasopathies and Chromatinopathies as Examples. Frontiers in Neuroscience, 2017, 11, 587.	1.4	19
358	Extra-uterine growth restriction in preterm infants: Neurodevelopmental outcomes according to different definitions. European Journal of Paediatric Neurology, 2021, 33, 135-145.	0.7	19
359	Multimodality evoked responses in the neurological assessment of the newborn. European Journal of Pediatrics, 1994, 153, 622-631.	1.3	18
360	Minor Neurological and Perceptuo-Motor Deficits in Children with Congenital Muscular Dystrophy: Correlation with Brain MRI Changes. Neuropediatrics, 1995, 26, 156-162.	0.3	18

#	Article	IF	Citations
361	The aetiology of delayed visual maturation: short review and personal findings in relation to magnetic resonance imaging. European Journal of Paediatric Neurology, 1997, 1, 31-34.	0.7	18
362	Delayed visual maturation in Karen refugee infants. Annals of Tropical Paediatrics, 2003, 23, 193-204.	1.0	18
363	Scale for Evaluation of Movement Disorders in the First Three Years of Life. Pediatric Neurology, 2009, 40, 258-264.	1.0	18
364	Choosing the right clinical outcome measure: From the patient to the statistician and back. Neuromuscular Disorders, 2011, 21, 16-19.	0.3	18
365	Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report. Neuromuscular Disorders, 2012, 22, 546-548.	0.3	18
366	Perceptual-motor abilities in pre-school preterm children. Early Human Development, 2013, 89, 809-814.	0.8	18
367	A New Self-Report Quality of Life Questionnaire for Children With Neuromuscular Disorders. Journal of Child Neurology, 2014, 29, 167-181.	0.7	18
368	Disorders of early language development in Dravet syndrome. Epilepsy and Behavior, 2016, 54, 30-33.	0.9	18
369	Sleep disorders in spinal muscular atrophy. Sleep Medicine, 2017, 30, 160-163.	0.8	18
370	Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function. Pediatric Physical Therapy, 2018, 30, 209-215.	0.3	18
371	Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care. Neurological Sciences, 2019, 40, 327-332.	0.9	18
372	Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy. Pediatric Pulmonology, 2020, 55, 1781-1788.	1.0	18
373	Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle and Nerve, 2021, 64, 552-559.	1.0	18
374	Neurodevelopmental evolution of West syndrome: A 2-year prospective study. European Journal of Paediatric Neurology, 2008, 12, 387-397.	0.7	17
375	SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe. Orphanet Journal of Rare Diseases, 2013, 8, 44.	1.2	17
376	Sleep-potentiated epileptiform activity in early thalamic injuries: Study in a large series (60 cases). Epilepsy Research, 2015, 109, 90-99.	0.8	17
377	New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients. Journal of Molecular Neuroscience, 2016, 59, 351-359.	1.1	17
378	RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design. Journal of Neuromuscular Diseases, 2020, 7, 145-152.	1.1	17

#	Article	IF	Citations
379	International retrospective natural history study of LMNA-related congenital muscular dystrophy. Brain Communications, 2021, 3, fcab075.	1.5	17
380	Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. European Journal of Pediatrics, 2022, 181, 2821-2829.	1.3	17
381	Applications of MRI in muscle diseases. Neuromuscular Disorders, 2012, 22, S41.	0.3	16
382	Neonatal neurological examination of late preterm babies. Early Human Development, 2013, 89, 537-545.	0.8	16
383	Calf muscle involvement in Becker muscular dystrophy: When size does not matter. Journal of the Neurological Sciences, 2014, 347, 301-304.	0.3	16
384	An unusual ryanodine receptor 1 (RYR1) phenotype. Neurology, 2019, 92, e1600-e1609.	1.5	16
385	Application of the Sleep Disturbance Scale for Children (SDSC) in infants and toddlers (6â€“36 months). Sleep Medicine, 2021, 81, 62-68.	0.8	16
386	Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module. Journal of Neuromuscular Diseases, 2021, 8, 589-601.	1.1	16
387	Severe Abnormalities of the Pons in Two Infants with Goldenhar Syndrome. Neuropediatrics, 2004, 35, 234-238.	0.3	15
388	Visual function assessment in late-preterm newborns. Early Human Development, 2012, 88, 301-305.	0.8	15
389	Somatic mosaicism in TPM2-related myopathy with nemaline rods and cap structures. Acta Neuropathologica, 2013, 125, 169-171.	3.9	15
390	Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscular Disorders, 2020, 30, 959-969.	0.3	15
391	Nusinersen in adults with spinal muscular atrophy: new challenges. Lancet Neurology, The, 2020, 19, 283-284.	4.9	15
392	Early white matter changes on brain magnetic resonance imaging in a newborn affected by merosin-deficient congenital muscular dystrophy. Neuromuscular Disorders, 2001, 11, 297-299.	0.3	14
393	Antenatal Post-hemorrhagic Ventriculomegaly: A Prospective Follow-up Study. Neuropediatrics, 2007, 38, 137-142.	0.3	14
394	Differential diagnosis of congenital muscular dystrophies. European Journal of Paediatric Neurology, 2008, 12, 371-377.	0.7	14
395	Childrenâ€™s Healthcare During Corona Virus Disease 19 Pandemic. Pediatric Infectious Disease Journal, 2020, 39, e137-e140.	1.1	14
396	Congenital Muscular Dystrophy. Pediatric Annals, 2005, 34, 560-568.	0.3	14

#	Article	IF	Citations
397	Spinal muscular atrophy: from rags to riches. Neuromuscular Disorders, 2021, 31, 998-1003.	0.3	14
398	Visual processing in Noonan syndrome: Dorsal and ventral stream sensitivity. American Journal of Medical Genetics, Part A, 2011, 155, 2459-2464.	0.7	13
399	Neurologic Assessment Tool for Screening Preterm Infants at Term Age. Journal of Pediatrics, 2012, 161, 1166-1168.	0.9	13
400	Evidence-based care in Duchenne muscular dystrophy. Lancet Neurology, The, 2018, 17, 389-391.	4.9	13
401	Neonatal hypotonia and neuromuscular conditions. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 162, 435-448.	1.0	13
402	P.353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, S184.	0.3	13
403	Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era. Italian Journal of Pediatrics, 2021, 47, 29.	1.0	13
404	Longitudinal data of neuropsychological profile in a cohort of Duchenne muscular dystrophy boys without cognitive impairment. Neuromuscular Disorders, 2021, 31, 319-327.	0.3	13
405	Spinal muscular atrophy: state of the art and new therapeutic strategies. Neurological Sciences, 2022, 43, 615-624.	0.9	13
406	SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples. ELife, 2021, 10, .	2.8	13
407	Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. Neuromuscular Disorders, 2022, 32, 36-42.	0.3	13
408	Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscular Disorders, 2022, 32, 271-283.	0.3	13
409	DIAPHRAGMATIC SPINAL MUSCULAR ATROPHY WITH BULBAR WEAKNESS. European Journal of Paediatric Neurology, 2000, 4, 69-72.	0.7	12
410	Visual development in infants with prenatal post-haemorrhagic ventricular dilatation. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2007, 92, F255-F258.	1.4	12
411	Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study. Neuromuscular Disorders, 2017, 27, S210.	0.3	12
412	Visual Function and Ophthalmological Findings in CHARGE Syndrome: Revision of Literature, Definition of a New Clinical Spectrum and Genotype Phenotype Correlation. Genes, 2021, 12, 972.	1.0	12
413	Sleep Disorders in Autism Spectrum Disorder Pre-School Children: An Evaluation Using the Sleep Disturbance Scale for Children. Medicina (Lithuania), 2021, 57, 95.	0.8	12
414	Visual function and EEG reactivity in infants with perinatal brain lesions at 1 year. Developmental Medicine and Child Neurology, 2002, 44, 171.	1.1	12

#	Article	IF	Citations
415	Hammersmith Infant Neurological Examination in infants born at term: Predicting outcomes other than cerebral palsy. Developmental Medicine and Child Neurology, 2022, 64, 871-880.	1.1	12
416	Responsiveness of the MD-Childhood Rating Scale in dyskinetic cerebral palsy patients undergoing anticholinergic treatment. European Journal of Paediatric Neurology, 2014, 18, 698-703.	0.7	11
417	Nusinersen in type 0 spinal muscular atrophy: should we treat?. Annals of Clinical and Translational Neurology, 2020, 7, 2481-2483.	1.7	11
418	Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019. Neuromuscular Disorders, 2020, 30, 431-436.	0.3	11
419	Hammersmith Infant Neurological Examination in lowâ€risk infants born very preterm: a longitudinal prospective study. Developmental Medicine and Child Neurology, 2022, 64, 863-870.	1.1	11
420	Visual Function in Children With Merosin-Deficient and Merosin-Positive Congenital Muscular Dystrophy. Pediatric Neurology, 1998, 18, 399-401.	1.0	10
421	Congenital Muscular Dystrophy with Short Stature, Proximal Contractures and Distal Laxity. Neuropediatrics, 2004, 35, 224-229.	0.3	10
422	Stakeholder collaboration for spinal muscular atrophy therapy development. Lancet Neurology, The, 2017, 16, 264.	4.9	10
423	Longitudinal assessments in discordant twins with SMA. Neuromuscular Disorders, 2017, 27, 890-893.	0.3	10
424	Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy?. Neuromuscular Disorders, 2018, 28, 863-864.	0.3	10
425	Early Neurological Assessment and Long-Term Neuromotor Outcomes in Late Preterm Infants: A Critical Review. Medicina (Lithuania), 2020, 56, 475.	0.8	10
426	Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen. Neuromuscular Disorders, 2021, 31, 310-318.	0.3	10
427	Neurological and visual assessments in very and late low-risk preterm infants. Early Human Development, 2012, 88, S31-S33.	0.8	9
428	Isolated semitendinosus involvement in the initial stages of limb-girdle muscular dystrophy 2L. Neuromuscular Disorders, 2014, 24, 1118-1119.	0.3	9
429	Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care?. Neuropediatrics, 2015, 46, 033-036.	0.3	9
430	Early visual and neuro-development in preterm infants with and without retinopathy. Early Human Development, 2020, 148, 105134.	0.8	9
431	Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy. Frontiers in Genetics, 2020, 11, 605.	1.1	9
432	Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen. European Journal of Neurology, 2021, 28, 602-608.	1.7	9

#	Article	IF	Citations
433	Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP. Ophthalmic Surgery Lasers and Imaging Retina, 2020, 51, 180-186.	0.4	9
434	Scientific rationale for a higher dose of nusinersen. Annals of Clinical and Translational Neurology, 2022, 9, 819-829.	1.7	9
435	Acetazolamide without frusemide in the treatment of postâ€haemorrhagic hydrocephalus. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 1319-1321.	0.7	8
436	Multiple Birth Versus Neonatal Brain Lesions in Children Born Prematurely as Predictors of Perceptuo-Motor Impairment at Age 6. Developmental Neuropsychology, 2003, 24, 435-459.	1.0	8
437	Current methodological issues in the study of children with inherited neuromuscular disorders. Developmental Medicine and Child Neurology, 2008, 50, 417-421.	1.1	8
438	T.P.1.07 Egen classification revisited in SMA. Neuromuscular Disorders, 2008, 18, 740-741.	0.3	8
439	Neonatal neurological examination during the first 6 h after birth. Early Human Development, 2017, 108, 41-44.	0.8	8
440	Effects of Lycra suits in children with cerebral palsy. European Journal of Paediatric Neurology, 2018, 22, 831-836.	0.7	8
441	Brain morphometry of preschool age children affected by autism spectrum disorder: Correlation with clinical findings. Clinical Anatomy, 2019, 32, 143-150.	1.5	8
442	A Recurrent Pathogenic Variant of INPP5K Underlies Autosomal Recessive Congenital Muscular Dystrophy With Cataracts and Intellectual Disability: Evidence for a Founder Effect in Southern Italy. Frontiers in Genetics, 2020, 11, 565868.	1.1	8
443	Familial Unilateral and Bilateral Occipital Calcifications and Epilepsy. Neuropediatrics, 1993, 24, 341-342.	0.3	7
444	Crossed cerebellar atrophy of prenatal onset. Child's Nervous System, 2006, 22, 734-736.	0.6	7
445	The empowerment of translational research: lessons from laminopathies. Orphanet Journal of Rare Diseases, 2012, 7, 37.	1.2	7
446	Interim analysis of the phase 3 CHERISH study evaluating nusinersen in patients with later-onset spinal muscular atrophy (SMA): Primary and descriptive secondary endpoints. European Journal of Paediatric Neurology, 2017, 21, e15.	0.7	7
447	Copy Number Variants Account for a Tiny Fraction of Undiagnosed Myopathic Patients. Genes, 2018, 9, 524.	1.0	7
448	Early Neurological Assessment in Infants with Hypoxic Ischemic Encephalopathy Treated with Therapeutic Hypothermia. Journal of Clinical Medicine, 2019, 8, 1247.	1.0	7
449	Sleep disorders in low-risk preschool very preterm children. Sleep Medicine, 2019, 63, 137-141.	0.8	7
450	Value of structured reporting in neuromuscular disorders. Radiologia Medica, 2019, 124, 628-635.	4.7	7

#	Article	IF	Citations
451	The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure. Neuromuscular Disorders, 2021, 31, 409-418.	0.3	7
452	Multicenter prospective longitudinal study in 34 patients with Dravet syndrome: Neuropsychological development in the first six years of life. Brain and Development, 2021, 43, 419-430.	0.6	7
453	Clinical and molecular genetic spectrum of autosomal dominant Emeryâ€Ðreifuss muscular dystrophy due to mutations of the lamin A/C gene. Annals of Neurology, 2000, 48, 170-180.	2.8	7
454	Visual and visuoperceptual function in children with Panayiotopoulos syndrome. Epilepsia, 2010, 51, 1205-1211.	2.6	6
455	Stem cells in severe infantile spinal muscular atrophy. Neuromuscular Disorders, 2012, 22, 1105.	0.3	6
456	Clinical, electrophysiological and pathological findings in a patient with Charcotâ€“Marieâ€“Tooth disease 4D caused by the NDRG1 Lom mutation. Journal of the Neurological Sciences, 2014, 345, 271-273.	0.3	6
457	Longitudinal assessment of perceptual-motor abilities in pre-school preterm children. Early Human Development, 2014, 90, 645-647.	0.8	6
458	Old measures and new scores in spinal muscular atrophy patients. Muscle and Nerve, 2015, 52, 435-437.	1.0	6
459	Efficacy of idebenone in Duchenne muscular dystrophy. Lancet, The, 2015, 385, 1704-1706.	6.3	6
460	SMA â€“ THERAPY. Neuromuscular Disorders, 2020, 30, S123-S124.	0.3	6
461	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. PLoS ONE, 2021, 16, e0253882.	1.1	6
462	Hypoglycaemia in patients with type 1 SMA: an underdiagnosed problem?. Archives of Disease in Childhood, 2020, 105, 707-707.	1.0	6
463	Muscle â€œislandsâ€• An MRI signature distinguishing neurogenic from myopathic causes of early onset distal weakness. Neuromuscular Disorders, 2022, 32, 142-149.	0.3	6
464	Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model. CNS Drugs, 2022, 36, 181-190.	2.7	6
465	Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. Journal of Neurology, 2022, 269, 4421-4435.	1.8	6
466	Auditory attention at the onset of West syndrome: Correlation with EEG patterns and visual function. Brain and Development, 2006, 28, 293-299.	0.6	5
467	Visual, motor and perceptual abilities at school age in children with isolated mild antenatal ventricular dilatation. Early Human Development, 2009, 85, 197-200.	0.8	5
468	Is there post-natal muscle growth in amyoplasia? A sequential MRI study. Neuromuscular Disorders, 2009, 19, 444-445.	0.3	5

#	Article	IF	Citations
469	Joint Laxity in Preschool Children Born Preterm. Journal of Pediatrics, 2018, 197, 104-108.	0.9	5
470	A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript â€œsingle-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1â€• written by pechmann and colleaguesâ€• European Journal of Paediatric Neurology, 2018, 22, 729-731.	0.7	5
471	Early involvement of the supinator muscle in Duchenne muscular dystrophy. Neuromuscular Disorders, 2018, 28, 62-63.	0.3	5
472	Cranial ultrasound evaluation in term neonates. Early Human Development, 2020, 143, 104983.	0.8	5
473	Assessing floppy infants: a new module. European Journal of Pediatrics, 2022, 181, 2771-2778.	1.3	5
474	The protein defect in congenital muscular dystrophy. Biochemical Society Transactions, 1996, 24, 281S-281S.	1.6	4
475	Visual function in children with hemiplegia in the first years of life. Developmental Medicine and Child Neurology, 2001, 43, 321-329.	1.1	4
476	Muscle MRI: Out of the tunnel. Neuromuscular Disorders, 2011, 21, 501-502.	0.3	4
477	Development of clinical signs in low risk term born infants with neonatal hyperexcitability. Early Human Development, 2013, 89, 65-68.	0.8	4
478	Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year follow-up report. Italian Journal of Pediatrics, 2015, 41, 64.	1.0	4
479	A Diagnostic Dilemma in a Family With Cystinuria Type B Resolved by Muscle Magnetic Resonance. Pediatric Neurology, 2015, 52, 548-551.	1.0	4
480	A prospective natural history study of type 1 spinal muscular atrophy. Nature Reviews Neurology, 2018, 14, 197-198.	4.9	4
481	O.41Sunfish part 1: 18-month safety and exploratory outcomes of risdiplam (RG7916) treatment in patients with type 2 or 3 spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, S208.	0.3	4
482	P.363JEWELFISH: safety and pharmacodynamic data in patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam (RG7916) that have previously been treated with nusinersen. Neuromuscular Disorders, 2019, 29, S187.	0.3	4
483	Clinical features and genetic analysis of two siblings with startle disease in an Italian family: a case report. BMC Medical Genetics, 2019, 20, 40.	2.1	4
484	Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy. Muscle and Nerve, 2019, 59, E42-E44.	1.0	4
485	SMA â€“ THERAPY. Neuromuscular Disorders, 2020, 30, S121.	0.3	4
486	Neural substrates of neuropsychological profiles in dystrophynopathies: A pilot study of diffusion tractography imaging. PLoS ONE, 2021, 16, e0250420.	1.1	4

#	Article	IF	Citations
487	Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy. Medicina (Lithuania), 2021, 57, 1267.	0.8	4
488	Longitudinal Cognitive Assessment in Low-Risk Very Preterm Infants. Medicina (Lithuania), 2022, 58, 133.	0.8	4
489	Occipito-Temporal Polymicrogyria and Subclinical Muscular Dystrophy. Neuropediatrics, 2003, 34, 92-95.	0.3	3
490	Diagnostic difficulties in a case of primary systemic carnitine deficiency with idiopathic dilated cardiomyopathy. European Journal of Paediatric Neurology, 2004, 8, 217-219.	0.7	3
491	Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy?. Neuromuscular Disorders, 2016, 26, 261-263.	0.3	3
492	P.223Respiratory function in SMA type 2 and non-ambulant SMA type 3, longitudinal data from the international SMA consortium (iSMAc). Neuromuscular Disorders, 2019, 29, S131-S132.	0.3	3
493	DMD & BMD â€“ CLINICAL. Neuromuscular Disorders, 2020, 30, S63-S64.	0.3	3
494	Spinal cord demyelination in children: A diagnostic challenge in neuropaediatrics for a good outcome. Brain and Development, 2020, 42, 457-461.	0.6	3
495	Ultrasound assisted lumbar intrathecal administration of nusinersen in adult patients with spinal muscular atrophy: A case series. Muscle and Nerve, 2021, 64, 594-599.	1.0	3
496	Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study. Acta Neuropathologica Communications, 2022, 10, 54.	2.4	3
497	Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients. Archives of Disease in Childhood, 2022, 107, 912-916.	1.0	3
498	Pregnancy-related psychopathology: A comparison between pre-COVID-19 and COVID-19â€“related social restriction periods. World Journal of Clinical Cases, 2022, 10, 6370-6384.	0.3	3
499	Developmental Coordination Disorder and Joint Hypermobility in Childhood: A Narrative Review. Children, 2022, 9, 1011.	0.6	3
500	G.P.2.04 Feeding problems and weight gain in spinal muscular atrophy. Neuromuscular Disorders, 2007, 17, 777-778.	0.3	2
501	Management of scoliosis in Duchenne muscular dystrophy: a large 10-year retrospective study. Developmental Medicine and Child Neurology, 2006, 48, 513-518.	1.1	2
502	Early Development of Epileptic Infants with Pre- or Perinatal Brain Injuries: Role of the Epileptic Disorder. Neuropediatrics, 2009, 40, 218-223.	0.3	2
503	The forward parachute reaction and independent walking in infants with brain lesions. Developmental Medicine and Child Neurology, 2011, 53, 636-640.	1.1	2
504	Muscular Dystrophies. , 2013, , 1-58.		2

#	Article	IF	Citations
505	G.P.114. Neuromuscular Disorders, 2014, 24, 829.	0.3	2
506	Spinal Muscular Atrophy Motor Functional Scales and Measures of Pulmonary Function. , 2017, , 371-382.		2
507	Predominant distal muscle involvement in spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 910-911.	0.3	2
508	Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): Global pivotal phase 3 study program (STR1VE-US, STR1VE-EU, STR1VE-AP). Journal of the Neurological Sciences, 2019, 405, 277-278.	0.3	2
509	Early Childhood Attention Battery: Italian adaptation and new expanded normative data. Early Human Development, 2020, 144, 105013.	0.8	2
510	Expanding the spectrum of congenital myopathies: prenatal onset with extreme hyperextension of the neck. Neurological Sciences, 2021, 42, 1549-1553.	0.9	2
511	Early Gross Motor Milestones in Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, 8, 453-456.	1.1	2
512	New Perspectives in the Management of Duchenne Muscular Dystrophy. European Neurological Review, 2014, 9, 78.	0.5	2
513	Autoimmune encephalopathies in children: diagnostic clues and therapeutic challenges. Neuroimmunology and Neuroinflammation, 2016, 3, 147.	1.4	2
514	Early Diagnosis and Treatment â€“ The Use of Ataluren in the Effective Management of Duchenne Muscular Dystrophy. European Neurological Review, 2018, 13, 31.	0.5	2
515	Body mass index in type 2 spinal muscular atrophy: a longitudinal study. European Journal of Pediatrics, 2022, , 1.	1.3	2
516	Cortical Thickness and Clinical Findings in Prescholar Children With Autism Spectrum Disorder. Frontiers in Neuroscience, 2021, 15, 776860.	1.4	2
517	Genetic modifiers of upper limb function in Duchenne muscular dystrophy. Journal of Neurology, 2022, 269, 4884-4894.	1.8	2
518	Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study. PLoS ONE, 2022, 17, e0267930.	1.1	2
519	Visual and perceptual function in children with congenital hemiplegia. Pediatric Neurology, 1994, 11, 161.	1.0	1
520	Neurological examination of the newborn. Current Paediatrics, 1999, 9, 42-50.	0.2	1
521	What's new in neuromuscular disorders?. European Journal of Paediatric Neurology, 2001, 5, 3-5.	0.7	1
522	Visual function and EEG reactivity in infants with perinatal brain lesions at 1 year. Developmental Medicine and Child Neurology, 2002, 44, 171-176.	1.1	1

#	Article	IF	Citations
523	P1.33 Disease progression observed in clinical outcome measures in placebo-treated patients with nonsense mutation dystrophinopathy. Neuromuscular Disorders, 2011, 21, 651.	0.3	1
524	P.2.1 The NorthStar Ambulatory Assessment in Duchenne Muscular Dystrophy: Considerations for the design of clinical trials. Neuromuscular Disorders, 2013, 23, 748.	0.3	1
525	P.2.7 6min walk test 12month changes in DMD: Correlation with genotype. Neuromuscular Disorders, 2013, 23, 750-751.	0.3	1
526	T.P.37. Neuromuscular Disorders, 2014, 24, 905.	0.3	1
527	G.O.23. Neuromuscular Disorders, 2014, 24, 922.	0.3	1
528	P167 â€“ 2623: The wide spectrum of neuropsychiatric profile in DMD in relation to underlying dystrophin gene mutations. European Journal of Paediatric Neurology, 2015, 19, S140-S141.	0.7	1
529	Longitudinal results of magneto-inertial motion analysis in Duchenne muscular dystrophy ambulant patients. Neuromuscular Disorders, 2016, 26, S184-S185.	0.3	1
530	Use of aÂâ‰¥Â5-second threshold in baseline time to stand from supine to predict disease progression in Duchenne muscular dystrophy. European Journal of Paediatric Neurology, 2017, 21, e237.	0.7	1
531	Olesoxime in patients with type 2 or non-ambulatory type 3 Spinal muscular atrophy: a placebo-controlled phase 2 trial including a long-term, open-label follow-up study. Neuromuscular Disorders, 2017, 27, S209-S210.	0.3	1
532	Neuromuscular disorders: 2017, a year to remember. Lancet Neurology, The, 2018, 17, 12-13.	4.9	1
533	SMA THERAPIES II AND BIOMARKERS. Neuromuscular Disorders, 2018, 28, S108.	0.3	1
534	Meta-analyses of ataluren in patients with nonsense mutation Duchenne muscular dystrophy. Neuromuscular Disorders, 2018, 28, S12.	0.3	1
535	Neurological assessment of late-preterm infants during the first year of age. European Journal of Paediatric Neurology, 2018, 22, 579-580.	0.7	1
536	P.267Modifiers of respiratory and cardiac function in the Italian Duchenne muscular dystrophy network and CINRG Duchenne natural history study. Neuromuscular Disorders, 2019, 29, S145.	0.3	1
537	SMA â€“ THERAPY. Neuromuscular Disorders, 2020, 30, S120-S121.	0.3	1
538	SMA â€“ THERAPY. Neuromuscular Disorders, 2020, 30, S123.	0.3	1
539	DMD â€“ THERAPY. Neuromuscular Disorders, 2020, 30, S129-S130.	0.3	1
540	Response to letter: A decision for life â€“ Treatment decisions in newly diagnosed families with spinal muscular atrophy. European Journal of Paediatric Neurology, 2021, 30, 103-104.	0.7	1

#	Article	IF	Citations
541	Circadian Genes as Exploratory Biomarkers in DMD: Results From Both the mdx Mouse Model and Patients. Frontiers in Physiology, 2021, 12, 678974.	1.3	1
542	Focus on the road to modelling cardiomyopathy in muscular dystrophy. Cardiovascular Research, 2022, 118, 1872-1884.	1.8	1
543	DMD - TREATMENT. Neuromuscular Disorders, 2021, 31, S94-S95.	0.3	1
544	DMD/BMD â€“ OUTCOME MEASURES. Neuromuscular Disorders, 2021, 31, S87.	0.3	1
545	Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. , 2000, 48, 170.		1
546	Neonatal Arterial Stroke. , 2012, , 1192-1198.		1
547	New Perspectives on the Diagnosis and Management of Duchenne Muscular Dystrophy. European Neurological Review, 2015, 10, 73.	0.5	1
548	De Novo Partial 13q22-q34 Trisomy with Typical Neurological and Immunological Findings: A Case Report with New Genetic Insights. Brain Sciences, 2021, 11, 21.	1.1	1
549	Early diagnostic and prognostic indicators in full term infants with neonatal cerebral infarction: an integrated clinical, neuroradiological and EEG approach. Minerva Pediatrica, 2001, 53, 305-11.	2.6	1
550	Muscle-MRI and Functional Levels for the Evaluation of Upper Limbs in Duchenne Muscular Dystrophy: A Critical Review of the Literature. Medicina (Lithuania), 2022, 58, 440.	0.8	1
551	The social smile in infants during the COVID-19 pandemia. Heliyon, 2021, 7, e08648.	1.4	1
552	Cerebral lesions in term infants with neonatal convulsions and normal Apgar score. Early Human Development, 1996, 45, 154-155.	0.8	0
553	Minor Neurological Signs and Perceptual-Motor Difficulties in Prematurely Born Children. Pediatric Physical Therapy, 1998, 10, 35.	0.3	0
554	La Risonanza Magnetica muscolare nelle malattie neuromuscolari. The Neuroradiology Journal, 2003, 16, 503-510.	0.1	0
555	C.P.2.05 Molecular analysis of COL6 genes in patients with Bethlem myopathy and Ullrich congenital muscular dystrophy. Neuromuscular Disorders, 2007, 17, 844-845.	0.3	0
556	G.P.15.16 Importance of self-report in pediatric quality of life assessment: Experience with the SOLE questionnaire in children with neuromuscular disorders. Neuromuscular Disorders, 2007, 17, 868-869.	0.3	0
557	C.P.3.02 Expanding the clinical spectrum of POMT1 and POMT2 phenotype: A multicentric study in the Italian population. Neuromuscular Disorders, 2007, 17, 869-870.	0.3	0
558	Cognitive competence at the onset of West syndrome: correlation with EEG patterns and visual function. Developmental Medicine and Child Neurology, 2005, 47, 760-765.	1.1	0

#	Article	IF	Citations
559	â€˜RandÃ² et al. replyâ€™. Developmental Medicine and Child Neurology, 2007, 48, 942-943.	1.1	0
560	Visual function in infants with brain lesions (1994). Developmental Medicine and Child Neurology, 2008, 50, 804-804.	1.1	0
561	G.P.1.04 Design of a novel array-CGH to explore allelic and genetic heterogeneity in COLVI related myopathies. Neuromuscular Disorders, 2008, 18, 731-732.	0.3	0
562	G.P.6.01 Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy. Neuromuscular Disorders, 2008, 18, 773.	0.3	0
563	EM.P.4.07 Autosomal recessive Bethlem myopathy. Neuromuscular Disorders, 2009, 19, 608-609.	0.3	0
564	M.P.5.03 Specificity and sensitivity of patterns of muscle MRI involvement in muscular dystrophies with rigidity of the spine. Neuromuscular Disorders, 2009, 19, 627-628.	0.3	0
565	Etiology of Perinatal Stroke; A Role for Prothrombotic Coagulation Factors?. Pediatric Research, 2011, 70, 215-215.	1.1	0
566	External hydrocephalus in discordant birth weight twins: a case report. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 337-340.	0.7	0
567	G.O.4 Search for SNPs modifiers in DMD with different corticosteroids response by candidate genes targeted resequencing. Neuromuscular Disorders, 2012, 22, 873-874.	0.3	0
568	Cerebral palsy, brain lesions, and thrombophilic genetic factors. Developmental Medicine and Child Neurology, 2012, 54, 100-100.	1.1	0
569	P.1.2 Natural history of pulmonary function in collagen VI-related myopathies: An international study. Neuromuscular Disorders, 2013, 23, 741-742.	0.3	0
570	P.2.3 Assessment of Upper Limb function in DMD patients: Comparison with normative data. Neuromuscular Disorders, 2013, 23, 749.	0.3	0
571	Perinatal brain lesions and cognitive outcome. Developmental Medicine and Child Neurology, 2013, 55, 881-882.	1.1	0
572	T.P.36. Neuromuscular Disorders, 2014, 24, 904-905.	0.3	0
573	T.P.11. Neuromuscular Disorders, 2014, 24, 863.	0.3	0
574	Congenital Muscular Dystrophies. , 2015, , 538-550.		0
575	MYH7-related myopathies: Clinical, histopathological and imaging findings in a cohort of Italian patients. Neuromuscular Disorders, 2015, 25, S281-S282.	0.3	0
576	miRNAs as serum biomarkers for Duchenne muscular dystrophy: Correlation analysis in a multicentre study between miRNA levels and clinical status of DMD patients. Neuromuscular Disorders, 2015, 25, S252.	0.3	0

#	Article	IF	Citations
577	Revised Hammersmith scale for spinal muscular atrophy: Longitudinal changes over six and twelve months in a large international cohort. Neuromuscular Disorders, 2016, 26, S104.	0.3	0
578	Muscle MR pattern of partial Laminin Î±2 deficient patients and its role in diagnostic algorithms. European Journal of Paediatric Neurology, 2017, 21, e234.	0.7	0
579	Accelerating the translation of natural history into more effective clinical trial design through multi-stakeholder collaboration. Neuromuscular Disorders, 2017, 27, S231-S232.	0.3	0
580	Laboratory Assessment of the Child with Suspected Neuromuscular Disorders. , 2017, , 1038-1043.		0
581	SMA THERAPIES II AND BIOMARKERS. Neuromuscular Disorders, 2018, 28, S110.	0.3	0
582	SMA THERAPIES II AND BIOMARKERS. Neuromuscular Disorders, 2018, 28, S109-S110.	0.3	0
583	P.063 SUNFISH Part 1 results and Part 2 trial design in patients with type 2/3 spinal muscular atrophy (SMA) receiving risdiplam (RG7916). Canadian Journal of Neurological Sciences, 2019, 46, S31.	0.3	0
584	P.151Motor performances in exon-2 duplication of the dystrophin gene. Neuromuscular Disorders, 2019, 29, S92-S93.	0.3	0
585	MUSCLE IMAGING â€“ MRI. Neuromuscular Disorders, 2020, 30, S95-S96.	0.3	0
586	SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES. Neuromuscular Disorders, 2020, 30, S96-S97.	0.3	0
587	SMA â€“ THERAPY. Neuromuscular Disorders, 2020, 30, S126-S127.	0.3	0
588	NEW GENES AND DISEASES / NGS & RELATED TECHNIQUES. Neuromuscular Disorders, 2020, 30, S141-S142.	0.3	0
589	Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies. Brain Sciences, 2020, 10, 156.	1.1	0
590	Reader Response: Nusinersen in Adult Patients With Spinal Muscular Atrophy: Observations From a Single Center. Neurology, 2021, 96, 1061-1062.	1.5	0
591	The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 479-488.	0.3	0
592	Reply to: The need for evidenceâ€based treatment decisions in spinal muscular atrophy type 0. Annals of Clinical and Translational Neurology, 2021, 8, 2093.	1.7	0
593	SMA - TREATMENT. Neuromuscular Disorders, 2021, 31, S138-S139.	0.3	0
594	SMA - TREATMENT. Neuromuscular Disorders, 2021, 31, S136.	0.3	0

#	Article	IF	Citations
595	RandÃ² et al. reply. Developmental Medicine and Child Neurology, 2006, 48, 942.	1.1	0
596	Neonatal Neuromuscular Disorders. , 2012, , 892-900.		0
597	Il profilo dei deficit neuropsicologici cognitivi della malattia di Duchenne: uno studio empirico controllato e le sue ricadute psicoter apiche. Quaderni Di Psicoterapia Cognitiva, 2019, , 40-55.	0.1	0
598	Study Design of STR1VE-EU, a Phase 3 Trial of AVXS-101 Gene-Replacement Therapy (GRT) in Patients With Spinal Muscular Atrophy Type 1 (SMA1) in Europe. , 2019, 50, .		0
599	Effect of Ataluren on Age at Loss of Ambulation in Nonsense Mutation Duchenne Muscular Dystrophy: Observational Data from the STRIDE Registry. , 2019, 50, .		0
600	Respiratory function and therapeutic expectations in DMD: families experience and perspective. Acta Myologica, 2020, 39, 121-129.	1.5	0
601	Pulmonary Function in Nonambulatory Patients with nmDMD from the STRIDE Registry and CINRG Duchenne Natural History Study: A Matched Cohort Analysis. , 2021, 52, .		0
602	Intravenous immunoglobulin for Pediatric Neuropsychiatric Lupus Triggered by Epstein-Barr Virus Cerebral Infection. Israel Medical Association Journal, 2016, 18, 763-766.	0.1	0